Finance

Beta
Lists
BLRX:NASDAQ
BioLine RX Ltd - ADR
$3.48
-7.94%
(-0.30) 1D
Jun 1, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BLRX...
Open
$3.77
High
$3.77
Low
$3.44
Mkt. cap
13.71M
Avg. vol.
85.51K
Volume
76.00
52-wk high
$6.59
52-wk low
$2.16
EPS
-$0.49
Beta
1.42
Shares outstanding
4.37M
No. of employees
22
Open
$3.77
High
$3.77
Low
$3.44
Mkt. cap
13.71M
Avg. vol.
85.51K
Volume
76.00
52-wk high
$6.59
52-wk low
$2.16
EPS
-$0.49
Beta
1.42
Shares outstanding
4.37M
No. of employees
22
News stories
From sources across the web
Profile
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Wikipedia
About BioLine RX Ltd - ADR
CEOPhilip A. Serlin
Employees22
Founded2003
Headquarters-
SectorBiotechnology
Websitebiolinerx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
304.00K
427.00K
194.00K
477.00K
Cost of goods sold
72.00K
84.00K
40.00K
95.00K
Cost of revenue
72.00K
84.00K
40.00K
95.00K
Research and development expenses
2.33M
1.72M
2.42M
2.53M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
209.00K
831.00K
1.12M
858.00K
Operating expense
2.54M
2.55M
3.54M
3.39M
Total operating expenses
2.61M
2.63M
3.58M
3.48M
Operating income
-2.30M
-2.21M
-3.39M
-3.00M
Other non operating income
-1.85M
1.16M
1.10M
666.00K
EBT including unusual items
-3.94M
-977.00K
-2.24M
-2.59M
EBT excluding unusual items
-3.94M
-977.00K
-2.24M
-2.59M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-3.94M
-977.00K
-1.38M
-1.60M
Net profit margin
-1,296.05%
-228.81%
-713.92%
-335.64%
Earnings per share
-
-
-
-
Interest and investment income
490.00K
377.00K
-
-
Interest expense
-276.00K
-304.00K
-288.00K
-250.00K
Net interest expenses
214.00K
73.00K
-288.00K
-250.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.13M
-2.09M
-3.33M
-2.92M
Gain or loss from assets sale
-
-
25.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer